Современные подходы в лечении метастазов в кости рака молочной железы: от бисфосфонатов к таргетной терапии

Современные подходы в лечении метастазов в кости рака молочной железы: от бисфосфонатов к таргетной терапии

Автор: Большакова Светлана Алексеевна, Бычков Юрий Маркович

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры, лекции

Статья в выпуске: 4 т.16, 2016 года.

Бесплатный доступ

При раке молочной железы часто наблюдается метастазирование в кости. Использование костно-таргетной терапии в виде бисфосфонатов или деносумаба рекомендуется всем пациентам с метастазами в кости рака молочной железы. Выбор между этими двумя группами препаратов остается открытым. В статье обсуждается эффективность костно-таргетной терапии, использование онкомаркеров в качестве предсказателя эффективности, вопросы безопасности применения бисфосфонатов и деносумаба. Представлен алгоритм выбора тактики лечения. Обсуждены вопросы адъювантного использования бисфосфонатов. Представлены новые препараты, находящиеся на стадии изучения при метастатическом поражении костей при раке молочной железы.

Еще

Метастатический рак молочной железы, костные метастазы, костнотаргетная терапия, бисфосфонаты, деносумаб

Короткий адрес: https://sciup.org/14955529

IDR: 14955529

Список литературы Современные подходы в лечении метастазов в кости рака молочной железы: от бисфосфонатов к таргетной терапии

  • Большакова С.А. Метастазы в кости рака молочной железы: механизм развития, осложнения, современный взгляд на сочетание бисфосфонатов и лучевой терапии. Вестник Российского научного центра рентгенорадиологии.2012.
  • Aft R., Naughton M., Trinkaus K., et al. Effect of zoledronic acid on disseminated tumor cells in women with locally advanced breast cancer: An open label, randomized, phase 2 trial. Lancet Oncol. 2010. V. 11. N. 5. P. 421-428.
  • Barret-Lee P., Casbard A., Abraham L., et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomized, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014. V. 15. N. 1. P. 114-122.
  • Blinc D., Nguyen N.D., Milch V.E., et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009. V. 301. N. 5. P. 513-521.
  • Block G.A., Bone H.G., Fang.L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012. V. 27. N. 7. P. 1371-1479.
  • Body J.J., Diel I.J., Lichinitser M.R., et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomizeplacebo-controlled phase III studies. Br J Cancer. 2004. V. 90. N. 6. P. 1133-1137.
  • Body J.J, Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003. V. 14. N. 9. P. 1399-1405.
  • Boyle W.J., Simonet W.S., Lacey O.D. Osteoclast differentiation and activation. Nature. 2003. V. 423. P. 337-342.
  • Brown J.E., Colemann R.E. Denosumab in patients with cancer -a surgical strike against the osteoclast. Nat Rev Clin Oncol. 2012. V. 9. N. 2. P. 110-118.
  • Brufsky A.M., Bosserman L.D., Caradonna R.R., et al. Zoledronic acid effectively prevents aromatase inhibitor -associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36 month follow-up results. Clin Breast Cancer. 2009. V. 9. N. 2. P. 77-85.
  • Brufsky A.M., Harker W.G., Beck J.T., et al. Final 5-yaer results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast Cancer patients receiving letrozole. Cancer. 2012. V. 118. N. 5. P. 1192-1201.
  • Campone M., Bondarenko I., Brincat S., et al. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol. 2012. V. 23. N. 3. P. 610-617.
  • Clemens M.J., Dranitsaris G., Ooi W.S., et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal -related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol. 2006. V. 24. P.4895-4900.
  • Clemons M., Dramitsaris G., Ooi W., Cole D.E. A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat. 2008. V. 108. N. 1. P. 79-85.
  • Coleman R., Bundred N., de Boer R., et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FASR, Z)-FAST and E-ZOFAST. Cancer Res. 2009. V. 69. (24 Suppl) P. 4082.
  • Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005. V. 23. N. 22. P. 4925-4935.
  • Coleman R.E., Marshall H., Cameron D., et al. AZURE Investigators. Breast cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011. V. 365. N. 15. P. 1396-1405.
  • Colemdn R., Body J.J., Aapro M., et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014. V. 25. (supple 3). iii124-137.
  • Daubine F., Le Gall C., Gasser J., et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastases. J Natl Cancer Inst. 2007. V. 99. P. 322-330.
  • De Boer R., Bundred N., Eidtmann H., et al. Long-term survival outcomes among postmenopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5-year follow-up of ZO-FAST. Cancer Res. 2011. V. 71. (24 supple). S1-S3.
  • Eidtmann H., de Boer R., Bundred N., et al. Efficacy of zolendronic zcid in poatmenopausal women with early breast cancer receiving adjuvant petrozole: 36-month resulta of the ZO-FAST study. Ann Oncol. 2010. V. 21. N. 11. P. 2188-2194.
  • Fizazi K., Lipton A., Mariette X., et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009. V. 27. N. 10. P. 1564-1571.
  • Gallo M., Le Luca A., Lamura L., et al. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for breast cancer. Ann Oncol. 2012. V. 23. N. 3. P. 597-604.
  • Gnaut M., Mlineritsch B., Luschin-Ebengreuth G., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008. V. 9. N. 9. P. 840-849.
  • Guant M., Mineritsch B., Stoeger H., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early stage breast cancer: 62-month follow-up from the ABCSG-12 randomized trial. Lancet Oncol. 2011. V. 12. N. 7. P. 631-641.
  • Guise T.A. Parathyroid hormone-related protein and bone metastases. Cancer. 1997. V. 80. P. 1572-1580.
  • Hadji P., Coleman R., Guant M. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everilimus. Crit Rev Oncol Hematol. 2013. V. 87. N. 2. P. 101-111.
  • Hadji P., Kauka A., Bauer T., et al. Influence of acid on BMD in premenopausal women with breast cancer and neoadjuvant or adjuvant chemotherapy and/or endocrine treatment -the ProBone studies. Cancer Res. 2011. V. 71. (24 supple). P2-19-03.
  • Hatoum H.T., Lin S.J., Smith M.R., et al. Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastases. Clin Breast Cancer. 2011. V. 11. N. 3. P. 177-183.
  • Hauschka P.V., Mavrakos A.E., Iafrati M.D., et al. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin -Sepharose. J Biol Chem. 1986. V. 261. N. 27. P. 12665-12674.
  • He M., Fan W., Zhang X. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis. J Hematol Oncol. 2013. V. 6. N. 1. P. 80.
  • Henry D., Vadhan-Raj S., Hirsh V., et al. Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advance cancer: an analysis of data, from patients with solid tumors. Support Care Cancer. 2014. V. 22. N. 3. P. 679-687.
  • Hershman D.L., McMahon G.J., Crew K.D., et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuating treatment. J Clin Endocrinol Metab. 2010. V. 95. N. 2. P. 559-566.
  • Hines S.L., Mincey B., Deutcher T., et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen -N033CC. Breast Cancer Res Treat. 2009. V. 117. P. 603-609.
  • Hortobagyi G.N., Theriault R.L., Lipton A., et al. Long term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998. V. 16. P. 2038-2044.
  • Jensen A.B., Wynne C., Ramiry G., et al. The cathepsin K inhibitor odanacathib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer. 2010. V. 10. P. 452458.
  • Kayamori K., Sakamoto K., Nakashima T., et al. Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukine-6 synthesized by stromal cells in response to cancer cells. Am J Pathol. 2010. V. 176. P. 968-80.
  • Kim J.E., Ahn J.H., Jung K.H., et al. Zoledronic acid prevents bone loss in postmenopausal women with early breast cancer undergoing adjuvant chemotherapy: A phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat. 2011. V. 125. P. 99-106.
  • Krentle V., Blum C., Meier C., et al. Bisphosphonate induced hypocalcaemia -report of six cases and review of the literature. Swiss med Wkly. 2014. V. 144. w13979.
  • Kristensen B., Ejlertsen B., Groenvold M., et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med. 1999. V. 246. P. 67-74.
  • Kudo O., Sabokbar A., Pocock A., et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL -independent mechanism. Bone. 2003. V. 32. P. 1-7.
  • Leal T., Tevaarwerk A., Love R., et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high -risk breast cancer. Clin Breast Cancer. 2010. V. 10. N. 6. P. 471-476.
  • Lipton A., Cook R., Saad F., et al. Normalization of bone markers is associated with improved survival in patient with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008. V. 113. P. 193-201.
  • Lipton A., Eizazik K., Stopeck A.T., et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomized, phase III trial. Eur J Cancer. 2012. V. 48. P. 3082-3092.
  • Lipton A., Steger G.G., Figueroa J., et al. Randomize active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer -related bone metastases. J Clin Oncol. 2007. V. 25. P. 4431-4437.
  • Mauri D., Valachis A., Polyzos N.P., et al. Does adjuvant bisphosphonate in early breast cancer modify the natural cause of the disease? A meta -analysis of randomize controlled trials. J Natl Compr Canc Netw. 2010. V. 8. P. 279-286.
  • Milat F., Goh S., Gani L.U., et al. Prolonged hypocalcaemia following denosumab therapy in metastatic hormone refractory prostate cancer. Bone. 2013. V. 55. P. 305-308.
  • Morris P.G., Lynch C., Funey J.N., et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol. 2010. V. 28. P. 3154-3159.
  • Mortimer J.E., Pal S.K. Safety considerations for use of bone-targeted agents in patients with cancer. Semin Oncol. 2010. V. 37suppl 1. S66-72.
  • Muller A., Honey B., Soto H., et al. Involvment of chemokine receptors in breast cancer metastases. Nature. 2001. V. 410. N. 6824. P. 50-56.
  • Nancollas G.H., Tang R., Phipps R.J., et al. Novel insights into actions of bisphosphonates on bone: Differences in interaction with hydroxyapatite. Bone. 2006. V. 38. P. 617-627.
  • Ohshiba T., Miyaura C., Ito A. Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastases. Biochem Biophys Res Commun. 2003. V. 300. P. 957-964.
  • Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastases Rev. 1989. V. 8. P. 98-101.
  • Paterson A.H., Powles T.J., Kanis J.A., et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993. V. 11. P. 5965.
  • Paul D., Vuikelja S.J., Holmes F.A., et al. Letrozole plus dasatinib improves progressionfree survival (PFS) in hormone receptor -positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy. Cancer Res. 2012. V. 73 (24 suppl.). abstr S3-07.
  • Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001. V. 7. N. 5. P. 377-387.
  • Rosen L.S., Gordon D.H., Dugan W.Jr., et al. Zoledronic acdi is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004. V. 100. N. 1. P. 36-43.
  • Rosen L.S., Goron D.H., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003. V. 98. N. 8. P. 1735-1744.
  • Rossi E., Morabito A., Di Rella F., et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer. The HOBOE trial. J Clin Oncol. 2009. V. 27. N. 19. P. 3192-3197.
  • Russell R.G. Bisphosphonates: the first 40 years. Bone. 2011. V. 49. N. 1. P. 2-19.
  • Russell R.G. Determinations of structure-function relationships among bisphosphonates. Bone. 2007. V. 40. P. S21-S25.
  • Saad F., Brown J.E., Van Poznak C., et al. Incidence, risk factors an outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012. V. 23. N. 5. P. 1341-1347.
  • Safra T., Berustein-Molho R., Greenberg.J, et al. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: A prospective, randomized, phase II trial. Oncology. 2011. V. 81. N. 5-6. P. 298-305.
  • Senarante S.G., Pirianov G., Mausi J.L., et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000. V. 82. N. 8. P. 1459-1468.
  • Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprogerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997. V. 89. N. 2. P. 309-19.
  • Stopeck A.T., Lipton A., Body J.J., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, doubleblind study. J Clin Oncol. 2010. V. 28. P. 5132-5139.
  • Swenson K.K., Nissen M.J., Anderson E., et al. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. J Support Oncol. 2009. V. 7. P. 101-107.
  • Takahashi S., Iwase T., Kohno N., et al. Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat. 2012. N. 133. P. 685-693.
  • Therault R.L., Lipton A., Hortobagyi G.N., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999. V. 17. N. 3. P. 846-54.
  • Tubiana-Hulin M., Benzeboc P., Mauriac L., et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer. 2001. V. 88. P. 701-707.
  • Valachis A., Polyzos N.P., Georgoullas V., et al. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta -analysis. Gynecol Oncol. 2010. V. 117. P. 139-145.
  • Van Poznak C.H., Temin S., Yee G.C., et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone modifying agents in metastatic breast cancer. J Clin Oncol. 2011. V. 29. P. 1221-1227.
  • Verdijk R., Franke H.R., Wolbers F., et al. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett. 2007. V. 246. P. 308-312.
  • Wang W., Wang E.G., Balthasar J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008. V. 84. P. 548-558.
  • Weitzman R., Sauter N., Eriksen E.F., et al. Critical review: updated recommendations for the prevention, diagnosis and treatment of osteonecrosis of the jaw in cancer patients -May 2006. Crit Rev Oncol Hematol. 2007. V. 62. P. 148-152.
  • Yan T., Yin M., Zhou Q., et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: A mets-analysis of randomized controlled trials. Eur J Clin. 2012. V. 48. P. 187-195.
Еще
Статья обзорная
SciUp 2024 © 2024 ©